DAY 4: Wednesday, September 24, 2025

Program subject to change.

07:00 - 17:00

Registration

07:15 - 08:15

Industry-Sponsored Symposia with Breakfast

  • Discovery Life Sciences

  • SCIEX

08:30 - 10:00

Concurrent Symposia 7 & 8

Symposium 7: Non-CYP Pathways

Co-Chairs: Bhagwat Prasad, Cincinnati Children's Hospital, USA; Mike Zientek, Treeline Biosciences, USA

  • The role of non-CYP enzymes in drug metabolism including novel drug modalities
    Deepak Ahire, Gilead Sciences, USA

  • Role of carboxylesterase and arylacetamide deacetylase in drug and lipid metabolism
    Tatsuki Fukami, Kanazawa Unviersity, Japan

  • Non-CYP enzymes in drug and prodrug design and development
    Rana Rais, Johns Hopkins, USA

Symposium 8: Humanized Animal Models

Co-chairs: Yukio Kato, Kanazawa University, Japan; Chitra Saran, Merck, USA

  • Acceleration of infectious disease drug discovery and development using a humanized model of drug metabolism
    Kevin Read, University of Dundee, UK

  • Pharmacogenomics, drug metabolism and pharmacokinetic study using chimeric NOG-TKm30 mice with humanized livers
    Hiroshi Yamazaki, Showa Pharmaceutical University, Japan

  • The humanized OATP1B rat model
    Jocelyn Yabut, Merck, USA

10:00 - 10:30

Break, Posters, Exhibitors

Thought Leader Presentation

  • CN Bio: 10:10 - 10:20

10:30 - 12:30

Concurrent Symposia 9 & 10

Symposium 9: DMET in Toxicology

Co-chairs: Eric Chan, National University of Singapore, Singapore; Albert Li, Discovery Life Sciences, USA

  • Implications of CYP2J2 in drug-induced cardiac adverse effects
    Eric Chan, National University of Singapore, Singapore

  • UGT inhibition and DILI potential
    Yvonne Will, USA

  • Bile acid transport and drug toxicity
    Chitra Saran, Merck, USA

  • Cytotoxic reactive metabolite formation as a key determinant of idiosyncratic liver toxicity
    Albert Li, Washington State University, USA

Symposium 10: Difficult-to-study and understudied? Model informed evidence with translational power

Co-chairs: Daniel Scotcher, University of Manchester, UK; Fei Hua, Certara, USA

  • Modeling the Silence: Translational PK/PD and IVIVC in siRNA Drug Development
    Sukyung Woo, The State University of New York at Buffalo, USA

  • Transforming the Development of Targeted Protein Degraders: The Translational Power of PK/PD Modeling beyond the Human Dose Projection
    Robin Haid, Bayer, Germany

  • Establishing a physiologically-based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase-CYP substrates
    Daniel Scotcher, University of Manchester, UK

  • Model-informed optimisation of treatment in pregnancy
    Saskia de Wildt, Radboud University Medical Center, Netherlands

12:00 - 15:00

Lunch/Exhibits/Poster Viewing/Thought Leader Presentations

Poster Session 3 Presentations, P127-P206
12:30 - 13:30: Odd Poster Presentations
13:30 - 14:30: Even Poster Presentations

Thought Leader Presentation Schedule
Labcorp: 12:45 - 12:55
SaiLife: 13:00 - 13:10

15:00 - 16:30

Symposia 11: Drug Discovery Tales

Co-chairs: Li Di, Recursion Pharmaceuticals, USA; Raju Subramanian, Gilead, USA

  • Expanding the Repertoire for “Large Small Molecules”: Challenges in developing an oral prodrug of the BCL-2 inhibitor Venetoclax
    Gary Jenkins, AbbVie, USA

  • The Story of Lenacapavir, a First-in-Class Long-Acting HIV Capsid Inhibitor, From Discovery to Clinical Development
    Raju Subramanian, Gilead, USA

  • Development Considerations for Tirzepatide: Drug Disposition Attributes
    Jennifer Martin, Lilly, USA

16:30 - 16:45

Closing Session